THE SCIENCE OF MS IS STILL UNDER CONSTRUCTION
We’re breaking down the science behind the condition to reconstruct a new understanding of MS that may build a better…
Australia MS News: Expensive MS drug (Mavenclad) to be on PBS next year
A drug used to treat people with multiple sclerosis has been added to the Pharmaceutical Benefits Scheme. www.9news.com.au · Dec…
Stuart Schlossman
Shots, Infusions, or Pills for Your MS?
DECEMBER 21, 2018 BY ED TOBIAS There are more than a dozen disease-modifying therapies available to treat MS. Some are…
Stuart Schlossman
Ocrevus Now Available Through NHS Scotland to Treat RRMS
Dec 12, 2018 Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with…
Stuart Schlossman
Video: Real Talk Multiple Sclerosis: The Escalation Model of MS
Escalation Therapy options – The Risks, The Benefits. Published by Aaron Boster, MD, (in his opinion). This video and the…
Stuart Schlossman
Ocrelizumab Reduces Risk of Upper Extremity Disability in PPMS Patients
A new assessment of ocrelizumab (Ocrevus) in patients with primary progressive multiple sclerosis (PPMS) has found the monoclonal antibody has capability to…
Stuart Schlossman
Teriflunomide for multiple sclerosis
Review article He D, et al. Cochrane Database Syst Rev. 2016. Show full citation Abstract BACKGROUND: This is an update of…
Stuart Schlossman
Hospital Charges $123,000 for Two MS Treatments
By Jay Hancock, Kaiser Health News Nov. 28, 2018 — Shereese Hickson’s multiple sclerosis was flaring again. Spasms in her…
Stuart Schlossman
Relapsing MS Therapy, Lemtrada, Carries Rare But Serious Risk of Stroke and Artery Tears, FDA Warns
December 2, 2018 The U.S. Food and Drug Administration (FDA) has issued a safety alert, warning about a rare but life-threatening risk of…
Stuart Schlossman
FDA Warns of Rare Risk of Severe Worsening in MS Disability After Stopping Gilenya Use
NOVEMBER 26, 2018 BY ANA PENA The U.S. Food and Drug Administration (FDA) has issued a safety alert, warning that people with relapsing multiple sclerosis (MS) who stop…
Stuart Schlossman
